About the company

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.


Health Technology


Pharmaceuticals: Generic




Heather M. Bresch





Total Revenue




Market Capitalization


Price/Earning ratio

Stock price

Gross Margin (in %)

Total gross margin


Operating Margin (in %)

Total operating margin


Net Margin (in %)

Total net margin


Dividend Yield (in %)

Dividend per share


Industry peers

Name Ticker Market capitalization (in USD Million) Revenues (in USD Million) Price/Book Price/Earning Net margin (in %)
Zoetis, Inc. ZTS 66214.46 6339.00 23.73 41.22 25.41
Mylan NV MYL 8551.18 11624.00 0.76 137.83 0.54
BridgeBio Pharma, Inc. BBIO 3590.07 41.00 9.45 -12.36 -718.08
Taro Pharmaceutical Industries Ltd. TARO 2591.60 645.00 1.24 10.74 37.88
TherapeuticsMD, Inc. TXMD 377.19 58.00 -8.74 -1.93 -333.88
Abeona Therapeutics, Inc. ABEO 210.92 3.00 2.15 -2.07 75.95
LifeVantage Corp. LFVN 189.90 230.00 6.36 16.03 5.06
Kindred Biosciences, Inc. KIN 157.56 4.00 2.62 -2.31 None
Cocrystal Pharma, Inc. COCP 53.55 2.00 1.96 -0.92 -733.84
China Pharma Holdings, Inc. CPHI 26.40 10.00 3.16 -1.22 -214.63
Jaguar Health, Inc. JAGX 4.92 5.00 3.64 0.08 -887.14

Latest insider transactions

Date Role Name Transaction Quantity Quantity Owned After

Mylan prices its generic remdesivir in India at $64 per 100 mg vial

18h ago, source: YAHOO!

Mylan NV said on Monday it would launch a generic version of Gilead Sciences Inc's COVID-19 antiviral remdesivir in India at ...

Mylan gets DCGI nod for remdesivir in India, to launch at Rs 4,800 per vial to treat COVID-19

1d ago, source: Your Story

Mylan NV has received approval from DCGI to manufacture and market its remdesivir for restricted emergency use in the country ...

Mylan to Launch Generic Remdesivir Version in India at Rs 4,800 Per 100 Mg Vial

18h ago, source: YAHOO!

Mylan's version comes after two Indian drugmakers, Cipla Ltd and privately-held Hetero Labs Ltd, launched their generic ...

Mylan’s remdesivir will be available to patients in India in July at ₹4,800

1d ago, source: Mint

Mylan to manufacture Remdesivir in India at its injectables facilities.Drug has been approved in India for treatment of ...

Mylan to manufacture Covid-19 treatment for India

1d ago, source: The Business Journals

"Developing Desrem and bringing it to patients in India with such unprecedented speed is a testament to the strength of our global operations and scientific capabilities and our commitment to serving ...

Mylan secures regulatory nod for Remdesivir

1d ago, source: Business Line

Mylan will manufacture Remdesivir in India at its world-class injectables facilities, which also make product for the US and ...

Mylan gets DCGI nod for remdesivir in India

1d ago, source: The Tribune

Per 100 mg vial to cost Rs 4,800; Cipla and Hetero have also got permission to manufacture and market the drug for the treatment of COVID-19 Pharmaceutical major Mylan NV on Monday said it had ...

Portfolio items

Follow companies to create your optimal portfolio.
Refresh this page to see your newly added stocks.